The management of neoplastic disorders of haematopoiesis in children with Down's syndrome.
Lange
B
B
Division of Oncology, 3408 Wood Building, The Children's Hospital of Philadelphia, Philadelphia, PA 191904, USA. lange@e-mail.CHOP.edu
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D001215:Asparaginase / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004314:Down Syndrome / Q000150:complications* / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007938:Leukemia / Q000150:complications* / Q000235:genetics / Q000628:therapy*; D007951:Leukemia, Myeloid / Q000150:complications / Q000628:therapy; D008297:Male; D008423:Maternal Age; D009196:Myeloproliferative Disorders / Q000150:complications / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000235:genetics / Q000628:therapy; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D014750:Vincristine; D001215:Asparaginase; D011241:Prednisone; D003630:Daunorubicin